Report: More CRO upheaval expected as PPD scouts for a buyout deal

There's more M&A activity percolating in the fast-changing CRO business. The Wall Street Journal cites sources saying that PPD--with a $3.2 billion market cap--is sizing up a possible sale of the company. That move puts PPD up on the sales block with PRA, which could fetch more than a billion dollars for its private equity owner Genstar.

In a followup, Reuters reported this morning that PPD--which primarily provides late-stage research support--could spur bids of more than $4 billion, according to analysts, with offers of up to $35 a share. That news helped drive a spike in PPD's share price.

Over the past couple of years the CRO business has undergone some major changes as Big Pharma turned to strategic partnerships with top firms to help them outsource more trial work. With CROs scrambling to do deals as the overall R&D pie has shrunk, the industry has also undergone a shakeout as the companies consolidate operations. Analysts expect the big CROs that dominate the business will control nearly half the market by 2015, giving private equity players like Genstar--which bought PRA for $700 million--an opportunity to capitalize on the buyout trend.

PPD has more than 11,000 staffers scattered around the globe in a business that brought in close to $1.5 billion in revenue last year. The company, whioch is based in Wilmington, NC, offers a global structure for drug development work.

Just days ago INC announced that it had closed a deal to buy Kendle for $232 million.

- here's the story from the Wall Street Journal
here's the report from Reuters

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.